The ability to efficiently deliver a drug to a tumor site is dependent on a wide range of
physiologically imposed design constraints. Nanotechnology provides the possibility of …

Physiological characteristics of diseases bring about both challenges and opportunities for
targeted drug delivery. Various drug delivery platforms have been devised ranging from …

Purpose Brentuximab vedotin, a monoclonal antibody (cAC10) conjugated to monomethyl
auristatin E, targets CD30+ receptors. This phase II open-label trial was conducted to …

The ability to efficiently deliver a drug or gene to a tumor site is dependent on a wide range
of factors including circulation time, interactions with the mononuclear phagocyte system …

Chemotherapy is an effortless and frequently used approach in cancer therapy. However, in
most cases, it can only prolong life expectancy and does not guarantee a complete cure …

Antibody drug conjugates (ADCs) are synthesized by conjugating a cytotoxic drug or
“payload” to a monoclonal antibody. The payloads are conjugated using amino or sulfhydryl …

Aptamers have excellent specificity and affinity in targeting cell surface receptors, showing
great potential in targeted delivery of drugs, siRNA, mRNA, and various nanomaterials with …

Despite relative success of therapy for Hodgkin's lymphoma (HL), novel therapeutic agents
are needed for patients with refractory or relapsed disease. Recently, anti-PD1 …

Os anticorpos monoclonais (mABs) têm sido indicados como tecnologia inovadora para o
tratamento de alguns tipos de câncer, por serem capazes de alvejar e matar seletivamente …

The clinical management of malignant tumours is challenging, often leading to severe
adverse effects and death. Drug resistance (DR) antagonises the effectiveness of …